1. Home
  2. NSRX vs RNXT Comparison

NSRX vs RNXT Comparison

Compare NSRX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nasus Pharma Ltd. Ordinary Shares

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$4.10

Market Cap

38.9M

Sector

Health Care

ML Signal

HOLD

Logo RenovoRx Inc.

RNXT

RenovoRx Inc.

N/A

Current Price

$1.67

Market Cap

42.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NSRX
RNXT
Founded
2019
2012
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.9M
42.4M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
NSRX
RNXT
Price
$4.10
$1.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$19.67
$8.25
AVG Volume (30 Days)
12.3K
526.4K
Earning Date
03-25-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
20.00
EPS
N/A
N/A
Revenue
N/A
$1,123,000.00
Revenue This Year
N/A
$194.66
Revenue Next Year
N/A
$279.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2511.63
52 Week Low
$1.98
$0.70
52 Week High
$9.50
$1.56

Technical Indicators

Market Signals
Indicator
NSRX
RNXT
Relative Strength Index (RSI) 64.61 67.76
Support Level $2.90 $0.83
Resistance Level $4.49 $1.51
Average True Range (ATR) 0.28 0.15
MACD 0.04 0.02
Stochastic Oscillator 89.52 82.26

Price Performance

Historical Comparison
NSRX
RNXT

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Share on Social Networks: